THERMO FISHER SCIENTIFIC INC.
For the period ended Sep 26, 2026. Filed Oct 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 26, 2026 · Filed Oct 30, 2026
TMO$718.20-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Equity
| Redeemable Noncontrolling Interest · Common Stock · Capital in Excess of Par Value · Retained Earnings · Treasury Stock · Accumulated Other Comprehensive Income/(Loss) · Total Thermo Fisher Scientific Inc. Shareholders’ Equity · Noncontrolling Interests · Total Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (In millions) · Shares · Amount · Shares · Amount | |||||||||||
| Balance at June 27, 2026 | $121 | 446 | $446 | $18,870 | $62,194 | 76 | $(26,370) | $(2,460) | $52,679 | $7 | $52,686 |
| Issuance of shares under stock plans | — | 1 | 1 | 282 | — | — | (43) | — | 240 | — | 240 |
| Stock-based compensation | — | — | — | 95 | — | — | — | — | 95 | — | 95 |
| Dividends declared ($0.47 per share) | — | — | — | — | (174) | — | — | — | (174) | — | (174) |
| Net income/(loss) | 5 | — | — | — | 1,721 | — | — | — | 1,721 | — | 1,722 |
| Other comprehensive income/(loss) | 1 | — | — | — | — | — | — | 196 | 196 | — | 196 |
| Contributions from (distributions to) noncontrolling interests | — | — | — | — | — | — | — | — | — | (1) | (1) |
| Excise tax from stock repurchases | — | — | — | — | — | — | 5 | — | 5 | — | 5 |
| Balance at September 26, 2026 | $128 | 447 | $447 | $19,247 | $63,740 | 76 | $(26,408) | $(2,264) | $54,761 | $6 | $54,767 |
| Balance at June 28, 2025 | $126 | 444 | $444 | $18,232 | $55,901 | 67 | $(21,269) | $(2,797) | $50,512 | $(35) | $50,476 |
| Issuance of shares under stock plans | — | — | — | 28 | — | — | (32) | — | (5) | — | (5) |
| Stock-based compensation | — | — | — | 70 | — | — | — | — | 70 | — | 70 |
| Purchases of company common stock | — | — | — | — | — | 2 | (1,000) | — | (1,000) | — | (1,000) |
| Dividends declared ($0.43 per share) | — | — | — | — | (163) | — | — | — | (163) | — | (163) |
| Net income/(loss) | 5 | — | — | — | 1,616 | — | — | — | 1,616 | 1 | 1,616 |
| Other comprehensive income/(loss) | (1) | — | — | — | — | — | — | (4) | (4) | — | (4) |
| Contributions from (distributions to) noncontrolling interests | — | — | — | — | — | — | — | — | — | (1) | (1) |
| Excise tax from stock repurchases | — | — | — | — | — | — | (9) | — | (9) | — | (9) |
| Disposition | — | — | — | — | — | — | — | — | — | 42 | 42 |
| Balance at September 27, 2025 | $129 | 445 | $445 | $18,330 | $57,354 | 69 | $(22,310) | $(2,801) | $51,018 | $7 | $51,024 |
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY (Continued)
| Redeemable Noncontrolling Interest · Common Stock · Capital in Excess of Par Value · Retained Earnings · Treasury Stock · Accumulated Other Comprehensive Income/(Loss) · Total Thermo Fisher Scientific Inc. Shareholders’ Equity · Noncontrolling Interests · Total Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (In millions) · Shares · Amount · Shares · Amount | |||||||||||
| Balance at December 31, 2025 | $122 | 445 | $445 | $18,563 | $59,156 | 69 | $(22,309) | $(2,448) | $53,407 | $7 | $53,415 |
| Issuance of shares under stock plans | — | 1 | 1 | 424 | — | — | (67) | — | 358 | — | 358 |
| Stock-based compensation | — | — | — | 261 | — | — | — | — | 261 | — | 261 |
| Purchases of company common stock | — | — | — | — | — | 7 | (4,000) | — | (4,000) | — | (4,000) |
| Dividends declared ($1.41 per share) | — | — | — | — | (524) | — | — | — | (524) | — | (524) |
| Net income/(loss) | 14 | — | — | — | 5,108 | — | — | — | 5,108 | 1 | 5,110 |
| Other comprehensive income/(loss) | (1) | — | — | — | — | — | — | 184 | 184 | — | 184 |
| Contributions from (distributions to) noncontrolling interests | (7) | — | — | — | — | — | — | — | — | (2) | (2) |
| Excise tax from stock repurchases | — | — | — | — | — | — | (33) | — | (33) | — | (33) |
| Balance at September 26, 2026 | $128 | 447 | $447 | $19,247 | $63,740 | 76 | $(26,408) | $(2,264) | $54,761 | $6 | $54,767 |
| Balance at December 31, 2024 | $120 | 444 | $444 | $17,962 | $53,102 | 63 | $(19,226) | $(2,697) | $49,584 | $(33) | $49,551 |
| Issuance of shares under stock plans | — | 1 | 1 | 142 | — | — | (58) | — | 85 | — | 85 |
| Stock-based compensation | — | — | — | 226 | — | — | — | — | 226 | — | 226 |
| Purchases of company common stock | — | — | — | — | — | 6 | (3,000) | — | (3,000) | — | (3,000) |
| Dividends declared ($1.29 per share) | — | — | — | — | (488) | — | — | — | (488) | — | (488) |
| Net income/(loss) | 13 | — | — | — | 4,740 | — | — | — | 4,740 | (1) | 4,738 |
| Other comprehensive income/(loss) | 5 | — | — | — | — | — | — | (103) | (103) | — | (103) |
| Contributions from (distributions to) noncontrolling interests | (8) | — | — | — | — | — | — | — | — | (2) | (2) |
| Excise tax from stock repurchases | — | — | — | — | — | — | (26) | — | (26) | — | (26) |
| Disposition | — | — | — | — | — | — | — | — | — | 42 | 42 |
| Balance at September 27, 2025 | $129 | 445 | $445 | $18,330 | $57,354 | 69 | $(22,310) | $(2,801) | $51,018 | $7 | $51,024 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.